Article
Medicine, General & Internal
Kazunori Adachi, Shunsuke Kato, Akira Koshino, Kazuhiro Nagao, Tomoya Sugiyama, Takashi Yoshimine, Yoshiharu Yamaguchi, Shinya Izawa, Wataru Ohashi, Masahide Ebi, Yasushi Funaki, Naotaka Ogasawara, Makoto Sasaki, Kunio Kasugai
Summary: This study assessed the efficacy of a vonoprazan (VPZ), clarithromycin (CAM), and metronidazole (MNZ) regimen in treating Helicobacter pylori infection in patients with clarithromycin resistance (CAM-R) and penicillin allergy. The results showed that the VCM regimen had a eradication rate of 94.3% and was effective for all patients with clarithromycin sensitivity (CAM-S). For patients with CAM-R, the success rate was 90.9%. Therefore, the VCM regimen may be a viable treatment option for patients with penicillin allergy, regardless of clarithromycin resistance.
Review
Medicine, General & Internal
Yingchao Sun, Mengjia Zhu, Lei Yue, Weiling Hu
Summary: This review provides an update on tetracycline-containing bismuth quadruple eradication therapy for H. pylori infection, reviewing the efficacy and safety of the regimens, aiming to provide guidance for clinical practice.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Infectious Diseases
Ligang Liu, Milap C. C. Nahata
Summary: Helicobacter pylori is a common cause of infections worldwide and its resistance to antibiotics is increasing. Amoxicillin is the preferred treatment, but many patients have penicillin allergy. For patients with true allergy, Vonoprazan-Clarithromycin-Metronidazole and bismuth quadruple therapy have shown excellent eradication rates. Vonoprazan-based therapy is better tolerated and can be considered as first-line treatment. Levofloxacin or sitafloxacin-based regimens have moderate eradication rates but potential serious adverse effects. Cephalosporins like cefuroxime can be an alternative to amoxicillin. Choosing the most effective antibiotic regimen can improve clinical outcomes in H. pylori infection with penicillin allergy.
Review
Gastroenterology & Hepatology
Antonia Valeria Borraccino, Francesca Celiberto, Maria Pricci, Bruna Girardi, Andrea Iannone, Maria Rendina, Enzo Ierardi, Alfredo Di Leo, Giuseppe Losurdo
Summary: When multiple Helicobacter pylori eradication treatments fail, a rifabutin-based regimen could be a viable alternative, as it demonstrates a low antibiotic resistance rate and high eradication rates when used in combination with amoxicillin or other antibiotics. However, caution should be exercised as rifabutin is commonly used for treating tuberculosis and may promote antibiotic resistance.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Yuxin Zhang, Baojun Suo, Xueli Tian, Hua Zhang, Haoping Lu, Xingyu Yao, Cailing Li, Xinlu Ren, Liya Zhou, Zhiqiang Song
Summary: This study compared the efficacy, safety, and compliance of three new bismuth quadruple therapies for first-line Helicobacter pylori eradication in penicillin-allergic patients. The therapies containing minocycline, cefuroxime, and full-dose metronidazole showed similar satisfactory results with good safety and compliance. This study is important for the treatment of penicillin-allergic patients.
Article
Gastroenterology & Hepatology
Chuan-Guo Guo, Feifei Zhang, Fang Jiang, Lingling Wang, Yijun Chen, Wenxue Zhang, Anni Zhou, Shutian Zhang, Wai K. Leung
Summary: This population-based retrospective cohort study aimed to determine whether H. pylori eradication therapy reduces the risk of colorectal cancer (CRC). The results showed that the risk of CRC was initially higher in H. pylori-infected subjects but gradually decreased over time and became lower than the general population after 10 years of H. pylori eradication, particularly for rectal cancer.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Olga P. Nyssen, Dmitry Bordin, Bojan Tepes, Angeles Perez-Aisa, Dino Vaira, Maria Caldas, Luis Bujanda, Manuel Castro-Fernandez, Frode Lerang, Marcis Leja, Luis Rodrigo, Theodore Rokkas, Limas Kupcinskas, Jorge Perez-Lasala, Laimas Jonaitis, Oleg Shvets, Antonio Gasbarrini, Halis Simsek, Anthony T. R. Axon, Gyorgy Buzas, Jose Carlos Machado, Yaron Niv, Lyudmila Boyanova, Adrian Goldis, Vincent Lamy, Ante Tonkic, Krzysztof Przytulski, Christoph Beglinger, Marino Venerito, Peter Bytzer, Lisette Capelle, Tomica Milosavljevic, Vladimir Milivojevic, Lea Veijola, Javier Molina-Infante, Liudmila Vologzhanina, Galina Fadeenko, Ines Arino, Giulia Fiorini, Ana Garre, Jesus Garrido, Cristina F. Perez, Ignasi Puig, Frederic Heluwaert, Francis Megraud, Colm O'Morain, Javier P. Gisbert
Summary: The study aimed to evaluate the decision-making and outcomes in Helicobacter pylori management by European gastroenterologists, finding that management of H. pylori infection is heterogeneous, with only quadruple therapies able to achieve over 90% eradication rates, and European recommendations are slowly and heterogeneously being incorporated into routine clinical practice.
Article
Gastroenterology & Hepatology
Ahmed Morad Asaad, Gasser El-Azab, Eman Abdelsameea, Osama Elbahr, Ahmed Kamal, Mohamed Abdel-Samiee, Ahmed Abdelfattah, Heba Abdallah, Doha Maher, Ahmed El-Refaie, Samar Ebrahim Ghanem, Shamshul Ansari, Samah Mohammed Awad
Summary: This study investigates H. pylori infection and resistance patterns in Egyptian patients, as well as the impact of H. pylori virulence genetic determinants on the success of 14-day triple therapy. The results show a low eradication rate with the triple therapy and high resistance to clarithromycin, amoxicillin, and metronidazole. Successful eradication is significantly associated with vacA s1-positive strains, while failed eradication is significantly associated with clarithromycin and amoxicillin-resistant strains.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Gastroenterology & Hepatology
Amit Kumar Dutta, Perminder Singh Phull
Summary: Treatment options for H.pylori infection in patients with penicillin allergy include first-line Bismuth-based quadruple therapy for 10-14 days, and second-line Levoflaxacin-based triple therapy for 10 days. Patients with persistent infection after 2 treatment courses should be tested for penicillin allergy, and treatment should be guided by H.pylori culture and sensitivity testing results.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Microbiology
Jingshu Chi, Canxia Xu, Xiaoming Liu, Hao Wu, Xiaoran Xie, Peng Liu, Huan Li, Guiying Zhang, Meihua Xu, Chaomin Li, Chunlian Wang, Fengqian Song, Ming Yang, Jie Wu
Summary: This study aimed to compare the efficacy and safety of doxycycline and amoxicillin in the first-line treatment of H. pylori-infected duodenal ulcers. The results showed that both treatments were effective and safe in H. pylori eradication, ulcer healing, and symptom relief. Only a small number of participants experienced adverse effects.
Article
Gastroenterology & Hepatology
Toshihiko Kakiuchi, Muneaki Matsuo, Hiroyoshi Endo, Yasuhisa Sakata, Motohiro Esaki, Takahiro Noda, Ichiro Imamura, Kazutoshi Hashiguchi, Shinichi Ogata, Yasuhiko Fujioka, Keiichiro Hanada, Kayoko Fukuda, Masaya Yoshimura, Tetsuro Kajiwara, Kentaroh Yamamoto, Daisuke Yamaguchi, Hiroharu Kawakubo, Taro Akashi, Michihiro Sumino, Keiji Matsunaga, Eriko Muro, Atsuo Kuwahara, Kazuto Taniguchi, Koji Fukuyama, Akira Watanabe, Ayako Takamori, Masumi Okuda, Kohei Yamanouchi, Kazuma Fujimoto
Summary: Evaluation of Helicobacter pylori infection screening and treatment in junior high students in Saga Prefecture, Japan. The success rate of eradication therapy was 87% among 274 students, with softer stool consistency observed in the eradication failure group on days 4, 5, and 6. Higher rates of abdominal pain and diarrhea were also found, with low incidence of other adverse events and only two students discontinuing treatment due to adverse effects.
Review
Infectious Diseases
Antonio Mestrovic, Nikola Perkovic, Ante Tonkic, Zeljko Sundov, Marko Kumric, Josko Bozic
Summary: The increase in antibiotic resistance to H. pylori has led to a decrease in the effectiveness of eradication therapy. Tailored therapy based on sensitivity tests to antibiotics is proving to be a superior option, even as a first-line therapy. Using a susceptibility-guided strategy and PCR technology can further optimize the eradication process.
Article
Infectious Diseases
Rongli Cui, Zhiqiang Song, Baojun Suo, Xueli Tian, Yan Xue, Lingmei Meng, Zhanyue Niu, Zhu Jin, Hejun Zhang, Liya Zhou
Summary: The study found that Helicobacter pylori has high resistance rates to clarithromycin and levofloxacin, and there is a correlation between resistance genes, phenotypic resistance, and clinical efficacy. Antibiotic sensitivity gene testing shows promising clinical application prospects.
INFECTION AND DRUG RESISTANCE
(2021)
Article
Gastroenterology & Hepatology
Ying-Chao Sun, Meng-Jia Zhu, Xue-Qin Chen, Lei Yue, Yi-Ru Zhao, Xin-Jie Wang, John J. Kim, Qin Du, Wei-Ling Hu
Summary: Evaluated the effect of modifying the tetracycline dose in quadruple therapy to improve safety and eradication rates in patients with H. pylori infection. The study found that the eradication rates were 92.40% in the modified dose group and 93.20% in the standard dose group, with no statistical difference. However, the incidence of adverse events was lower in the modified dose group compared to the standard dose group.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Youn Choi, Jun-Won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim, Jung Ho Kim, Ja Young Seo, Dong Kyun Park
Summary: The study compared the efficacy and safety of tailored therapy (TT) and concomitant therapy (CT) for Helicobacter pylori infection treatment. Results showed that the TT group had significantly lower treatment-related and patient-reported side effects compared to the CT group, but there were no significant differences in compliance, follow-up loss rates, and eradication success rate between the two groups.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Gastroenterology & Hepatology
Karen M. J. Waller, Rupert W. Leong, Sudarshan Paramsothy
Summary: FMT has become an established treatment for recurrent Clostridioides difficile infection and induction of remission for mild-moderate ulcerative colitis, but limited and conflicting data are available for other indications. Research is ongoing to explore the role of FMT in various conditions, while its mechanisms remain incompletely understood.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Craig Haifer, Laurence Don Wai Luu, Sudarshan Paramsothy, Thomas J. Borody, Rupert W. Leong, Nadeem O. Kaakoush
Summary: This study characterized the differences in gut microbiota between two FMT donors and found that donor microbiota stability and species evenness were associated with therapeutic efficacy in UC. These findings have important implications for improving FMT donor selection.
Article
Gastroenterology & Hepatology
Eleanor Liu, Robyn Laube, Rupert W. Leong, Aileen Fraser, Christian Selinger, Jimmy K. Limdi
Summary: Objective assessment shows that gastroenterology health care professionals have good knowledge of pregnancy-specific IBD, but there is inconsistency in applying this knowledge in decision-making. Further education for clinicians is needed to provide optimal standardized care for IBD in pregnancy.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Lucy Hocking, Gianluca Ianiro, Rupert W. Leong, Tariq Iqbal, Dina Kao, Mark Cabling, Stephanie Stockwell, Robert J. Romanelli, Sonja Marjanovic
Summary: This study explores the key components of faecal microbiota transplantation (FMT) provision for recurrent Clostridioides difficile infection (CDI) and highlights the challenges and improvement opportunities in healthcare capacity, donors and donations, patient access, regulation, costs, and reimbursement. The findings emphasize the importance of building appropriate FMT capacity to effectively bring FMT to patients in healthcare systems.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Medicine, General & Internal
Martin Harb, Jessica Yang, Rupert Leong
INTERNAL MEDICINE JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Aviv Pudipeddi, Caroline Fung, Britt Christensen, Robert Bryant, Kavitha Subramaniam, John Chetwood, Sudarshan Paramsothy, Rupert W. Leong
Summary: This study aimed to evaluate the knowledge and attitudes of gastroenterologists and pathologists towards histology guidelines and the use of histology in ulcerative colitis (UC). The survey results showed that almost all gastroenterologists and pathologists believed that histological assessment should be part of UC evaluation. However, they lacked awareness and understanding of histological scoring systems and their definitions.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A. Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig
Summary: This study aimed to compare the relapse rate and time in remission over 2 years between patients continuing combination therapy, stopping infliximab, or stopping immunosuppressant therapy for Crohn's disease. The results showed that stopping infliximab had a higher relapse rate compared to stopping immunosuppressant therapy, suggesting that stopping immunosuppressant therapy may be a preferable strategy for treatment de-escalation.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Emilia Anderson, Karen Waller, Aravind Gokul Tamilarasan, Huiyu Lin, Sudarshan Paramsothy, Rupert W. Leong
Summary: This article compares and contrasts originator and biosimilar adalimumab agents, identifying key differences such as product formulation, dosages available, delivery devices, physician support, patient support, and the supply of other biosimilar products by the company. Therefore, the choice of agent should be individualized to the needs of the patient and the healthcare service.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Letter
Gastroenterology & Hepatology
Eva Zhang, Thi H. O. Nguyen, Lilith F. Allen, Lukasz Kedzierski, Louise C. Rowntree, So Young Chang, Wuji Zhang, Jennifer R. Habel, Isabelle J. Foo, Tejas Menon, Jeni Mitchell, Rupert W. Leong, Katherine Bond, Deborah A. Williamson, Katherine Kedzierka, Britt Christensen
Review
Immunology
Philip J. Smith, Mathurin Fumery, Rupert W. Leong, Kerri Novak, Axel Dignass
Summary: This article provides an overview of the clinical trial and real-world data for the subcutaneous formulation of infliximab (IFX SC) for the treatment of inflammatory bowel disease (IBD). It highlights the potential benefits of switching from intravenous (IV) to SC administration and discusses therapeutic drug monitoring and patient perspectives. The evidence suggests that IFX SC is well tolerated and effective in patients with stable disease.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Letter
Gastroenterology & Hepatology
John David Chetwood, Sudarshan Paramsothy, Craig Haifer, Rupert W. Leong, Nadeem O. Kaakoush
Review
Medicine, General & Internal
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W. Leong
Summary: Biological therapy is a vital treatment for managing moderate-to-severe inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD). However, the selection of appropriate biological agents remains challenging. This study aims to compare the drug persistence of new-generation biologics with conventional anti-tumor necrosis factor alphas (anti-TNF alphas) in adult IBD patients.
Review
Gastroenterology & Hepatology
Alexander T. Elford, Rupert W. Leong, Emma P. Halmos, Manal Morgan, Kate Kilpatrick, Peter J. Lewindon, Richard B. Gearry, Britt Christensen
Summary: Australasia, including Australia, New Zealand, and Papua New Guinea, has a high prevalence of inflammatory bowel disease (IBD), and the practice of IBD medicine varies within this region. This review discusses barriers to IBD care across Australasia from the perspective of local healthcare professionals, including access to multidisciplinary teams, nutritional therapies, mental health disorders associated with IBD, medication availability, endoscopy access, rural barriers to care, Indigenous IBD care, and pediatric issues. The aim is to identify areas for improvement in IBD care and address research needs in Australasia.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Christian P. Selinger, Robyn Laube, Helen Steed, Matthew Brookes, Rupert W. L. NIHR BioResource, Rupert W. L. Leong
Summary: In female IBD patients, planning to conceive within the next year is associated with better medication adherence and greater disease-related knowledge.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Maria T. Abreu, Ellen J. Scherl, David S. Rowbotham, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Remo Panaccione, Waqqas Afif, Tadakazu Hisamatsu, Rupert W. Leong, Bruce E. Sands, Ramesh P. Arasaradnam, Colleen Marano
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)